BR9712204A - Composto, processos para preparar um composto, tratar inflamacão neurogênica e artrite reumatóide, composicão farmaceutica, composições farmacêuticas adequadas para tratar inflamacão neurogênica, para tratar neuropatia, para tratar artrite reumatóide, para reduzir glicose do sangue, para inibir a atividade do cgrp, para tratar enxaqueca, para tratar coceira, e uso de um composto - Google Patents

Composto, processos para preparar um composto, tratar inflamacão neurogênica e artrite reumatóide, composicão farmaceutica, composições farmacêuticas adequadas para tratar inflamacão neurogênica, para tratar neuropatia, para tratar artrite reumatóide, para reduzir glicose do sangue, para inibir a atividade do cgrp, para tratar enxaqueca, para tratar coceira, e uso de um composto

Info

Publication number
BR9712204A
BR9712204A BR9712204-1A BR9712204A BR9712204A BR 9712204 A BR9712204 A BR 9712204A BR 9712204 A BR9712204 A BR 9712204A BR 9712204 A BR9712204 A BR 9712204A
Authority
BR
Brazil
Prior art keywords
treating
compound
treat
neurogenic inflammation
rheumatoid arthritis
Prior art date
Application number
BR9712204-1A
Other languages
English (en)
Inventor
Henrik Sune Andersen
Tine Krogh Jorgensen
Rolf Hohlweg
Knud Erik Andersen
Zdenek Polivka
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of BR9712204A publication Critical patent/BR9712204A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"COMPOSTO, PROCESSOS PARA PREPARAR UM COMPOSTO, TRATAR INFLAMAçãO NEUROGêNICA E ARTRITE REUMATóIDE, COMPOSIçãO FARMACêUTICA, COMPOSIçõES FARMACêUTICAS ADEQUADAS PARA TRATAR INFLAMAçãO NEUROGêNICA, PARA TRATAR NEUROPATIA, PARA TRATAR ARTRITE REUMATóIDE, PARA REDUZIR GLICOSE DO SANGUE, PARA INIBIR A ATIVIDADE DO CGRP, PARA TRATAR ENXAQUECA, PARA TRATAR COCEIRA, E, USO DE UM COMPOSTO". A presente invenção refere-se a novos ácidos carboxíliocos azaeterocíclicos N-substituídos, de fórmula geral (I): em que X, Y, Z, R^ 1^, R^ 2^ e r são como definidos na pate detalhada da descrição, ou seus sais, a processos para sua preparação, a composições contendo-os e a seu uso para o tratamento clínico de condições dolorosas, hiperalgésicas e/ou inflamatórias, em que as fibras-C representam um papel patofisiológico, pela eliciação da dor ou inflamação neurogênica, bem como seu uso para tratamento de indicações causadas por ou relacionadas com a secreção e circulação de insulina antagonizando peptídeos.
BR9712204-1A 1996-10-04 1997-10-02 Composto, processos para preparar um composto, tratar inflamacão neurogênica e artrite reumatóide, composicão farmaceutica, composições farmacêuticas adequadas para tratar inflamacão neurogênica, para tratar neuropatia, para tratar artrite reumatóide, para reduzir glicose do sangue, para inibir a atividade do cgrp, para tratar enxaqueca, para tratar coceira, e uso de um composto BR9712204A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK108896 1996-10-04
PCT/DK1997/000420 WO1998015549A1 (en) 1996-10-04 1997-10-02 N-substituted azaheterocyclic compounds

Publications (1)

Publication Number Publication Date
BR9712204A true BR9712204A (pt) 1999-08-31

Family

ID=8100865

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9712204-1A BR9712204A (pt) 1996-10-04 1997-10-02 Composto, processos para preparar um composto, tratar inflamacão neurogênica e artrite reumatóide, composicão farmaceutica, composições farmacêuticas adequadas para tratar inflamacão neurogênica, para tratar neuropatia, para tratar artrite reumatóide, para reduzir glicose do sangue, para inibir a atividade do cgrp, para tratar enxaqueca, para tratar coceira, e uso de um composto

Country Status (21)

Country Link
US (1) US6004983A (pt)
EP (1) EP0934313B1 (pt)
JP (1) JP2001501937A (pt)
KR (1) KR20000048901A (pt)
CN (3) CN1084744C (pt)
AR (1) AR010237A1 (pt)
AT (1) ATE240320T1 (pt)
AU (1) AU740958B2 (pt)
BR (1) BR9712204A (pt)
CA (1) CA2267691A1 (pt)
CZ (1) CZ114299A3 (pt)
DE (1) DE69722022D1 (pt)
HU (1) HUP9904705A3 (pt)
IL (1) IL129121A (pt)
MX (1) MXPA99003106A (pt)
NO (1) NO991564L (pt)
PL (1) PL332592A1 (pt)
RU (1) RU2186769C2 (pt)
TW (1) TW420675B (pt)
WO (1) WO1998015549A1 (pt)
ZA (1) ZA978792B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613905B1 (en) * 1998-01-21 2003-09-02 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US7355042B2 (en) 2001-10-16 2008-04-08 Hypnion, Inc. Treatment of CNS disorders using CNS target modulators
US7541365B2 (en) 2001-11-21 2009-06-02 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
TWI291467B (en) 2002-11-13 2007-12-21 Millennium Pharm Inc CCR1 antagonists and methods of use therefor
WO2005003131A1 (en) 2003-06-27 2005-01-13 Janssen Pharmaceutica N.V. Tricyclic delta opioid modulators
AU2005335481A1 (en) * 2004-08-05 2007-04-19 Janssen Pharmaceutica N.V. Tricyclic delta- opioid modulators
EP1833825A1 (en) * 2004-12-22 2007-09-19 Janssen Pharmaceutica N.V. Tricyclic delta-opioid modulators
AU2005319059A1 (en) * 2004-12-22 2006-06-29 Janssen Pharmaceutica N.V. Tricyclic delta-opioid modulators
ATE432279T1 (de) * 2004-12-22 2009-06-15 Janssen Pharmaceutica Nv Tricyclische delta-opioid-modulatoren
MX2007008286A (es) * 2005-01-06 2007-11-12 Johnson & Johnson Moduladores delta-opioides triciclicos.
DE102005022020A1 (de) * 2005-05-12 2006-11-23 Merckle Gmbh Dibenzocycloheptanverbindungen und pharmazeutische Mittel, welche diese Verbindungen enthalten
TW200716134A (en) * 2005-06-16 2007-05-01 Janssen Pharmaceutica Nv Tricyclic opioid modulators

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY113463A (en) * 1994-01-04 2002-03-30 Novo Nordisk As Novel heterocyclic compounds
US5716949A (en) * 1995-04-07 1998-02-10 Novo Nordisk A/S Heterocyclic compounds
UA54385C2 (uk) * 1995-04-07 2003-03-17 Ново Нордіск А/С N-заміщені азагетероциклічні карбонові кислоти та їх ефіри, спосіб їх одержання, фармацевтична композиція та спосіб лікування
WO1997022338A1 (en) * 1995-12-15 1997-06-26 Novo Nordisk A/S Novel method

Also Published As

Publication number Publication date
CN1403454A (zh) 2003-03-19
DE69722022D1 (de) 2003-06-18
CN1403445A (zh) 2003-03-19
EP0934313A1 (en) 1999-08-11
NO991564D0 (no) 1999-03-30
JP2001501937A (ja) 2001-02-13
CN1191233C (zh) 2005-03-02
CZ114299A3 (cs) 1999-09-15
PL332592A1 (en) 1999-09-27
EP0934313B1 (en) 2003-05-14
AR010237A1 (es) 2000-06-07
CA2267691A1 (en) 1998-04-16
MXPA99003106A (es) 2004-12-02
IL129121A0 (en) 2000-02-17
RU2186769C2 (ru) 2002-08-10
NO991564L (no) 1999-06-04
HUP9904705A2 (hu) 2000-06-28
IL129121A (en) 2004-03-28
ZA978792B (en) 1998-04-06
US6004983A (en) 1999-12-21
AU740958B2 (en) 2001-11-15
ATE240320T1 (de) 2003-05-15
AU4377097A (en) 1998-05-05
CN1198820C (zh) 2005-04-27
WO1998015549A1 (en) 1998-04-16
HUP9904705A3 (en) 2000-09-28
CN1084744C (zh) 2002-05-15
CN1235603A (zh) 1999-11-17
TW420675B (en) 2001-02-01
KR20000048901A (ko) 2000-07-25

Similar Documents

Publication Publication Date Title
BR9712202A (pt) Composto, processo para preparar o mesmo, composicão farmacêutica, processo para o tratamento de inflamacão neurogênica em um indivíduo em necessidade deste tratamento, e, uso do composto.
EP0142860B1 (de) Desulfatohirudine, Verfahren zu ihrer Herstellung und pharmazeutische Mittel
Brenneman et al. Activity-dependent neurotrophic factor: structure-activity relationships of femtomolar-acting peptides
BR9712204A (pt) Composto, processos para preparar um composto, tratar inflamacão neurogênica e artrite reumatóide, composicão farmaceutica, composições farmacêuticas adequadas para tratar inflamacão neurogênica, para tratar neuropatia, para tratar artrite reumatóide, para reduzir glicose do sangue, para inibir a atividade do cgrp, para tratar enxaqueca, para tratar coceira, e uso de um composto
BR9806870A (pt) Composto, processo para a profilaxia ou tratamento de uma condição clìnica em um mamìfero, formulação farmacêutica, e, uso de um composto e processo para preparar o mesmo.
CA1161362A (en) Pharmaceutical compositions containing a corticosteroid substance
OA10917A (en) Antimicrobial treatment for herpes simplex virus and other infectious diseases
BR9907967A (pt) Composto de polipeptideo, processo para sua preparação, composição farmacêutica compreendendo dito composto, e seu uso.
BR9810911A (pt) Composto, e, processo para tratar câncer em um mamìfero
BR0010257A (pt) Composto, processo para a preparação de um composto, formulação farmacêutica, uso de um composto, método para tratamento ou profilaxia de condições associadas com a inibição da carboxipeptidase u, kits de partes, e, método de tratamento de um paciente sofrendo de ou susceptìvel a uma condição em que a inibição da carboxipeptidase u e um mecanismo antitrombótico diferente são necessários ou desejados
Geratz Inhibition of thrombin, plasmin and plasminogen activation by amidino compounds
EP1226829A2 (de) Stabilisierte Flüssigzubereitung der den Blutgerinnungsfaktor VII aktivierenden Protease oder ihres Proenzyms
BRPI0409884A (pt) compostos, composições farmacêuticas, método para o tratamento ou porfilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
EP0046979A1 (de) Analoga des Insulins
DK0696283T3 (da) 2-, 3,- 4,- 5,- 6,- 7,- 8,- 9,- og/eller 10 substituerede dibenzoxazepinforbindelser, lægemidler og anvendelser
BR9712196A (pt) Composto, uso do mesmo, processo para sua preparação e para tratar inflamação neurogênica, e, composições farmacêuticas para tratar inflamação neurogênica, para tratar neuropatia, para tratar artrite reumatóide, para reduzir glicose no sangue e/ou para inibir a atividade de cgrp, para tratar enxaqueca e para tratar coceira
WO2002072136A1 (en) Compositions and methods for stimulating wound healing and fibroblast proliferation
BRPI0409818A (pt) compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
EP0193175A2 (de) Modifizierte Hirudine, Verfahren zu deren Herstellung und pharmazeutische Mittel, die diese Wirkstoffe enthalten
EP0579488B1 (en) Composition for treating mastitis and metritis
BRPI0409881A (pt) compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
BR0006301A (pt) Macrólidos antibacterianos e pró-cinéticos
US4355025A (en) Biologically active amides
BR0010256A (pt) Composto, processo para a preparação de um composto, formulação farmacêutica, uso de um composto, método de tratamento ou profilaxia de condições associadas com a inibição da carboxipeptidase u, kit de partes, e, método de tratamento de um paciente sofrendo de ou susceptìvel a uma condição em que a inibição da carboxipeptidase u e um mecanismo antitrombótico diferente são necessários
DE69006931T2 (de) Ghilanten: antimetastatischer Wirkstoff aus dem südamerikanischen Blutegel Haementeria Ghilianii.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1868 DE 24/10/2006.